| high-speed atomic force microscopy reveals strongly polarized movement of clostridial collagenase along collagen fibrils. | bacterial collagenases involved in donor infection are widely applied in many fields due to their high activity and specificity; however, little is known regarding the mechanisms by which bacterial collagenases degrade insoluble collagen in host tissues. using high-speed atomic force microscopy, we simultaneously visualized the hierarchical structure of collagen fibrils and the movement of a representative bacterial collagenase, clostridium histolyticum type i collagenase (colg), to determine th ... | 2016 | 27373458 |
| evaluation of skin anti-aging potential of citrus reticulata blanco peel. | the peel of citrus reticulata blanco is traditionally used as tonic, stomachic, astringent, and carminative. it is also useful in skin care. | 2017 | 27365982 |
| efficacy and safety of collagenase clostridium histolyticum injection for dupuytren's contracture in non-caucasian japanese patients (cord-j study): the first clinical trial in a non-caucasian population. | to assess the efficacy, safety and pharmacokinetics of 0.58 mg collagenase clostridium histolyticum injections for the treatment of dupuytren's contracture in japanese patients, we conducted a phase iii, multicentre, uncontrolled, open-label clinical study in patients with dupuytren's contracture. of the 77 patients, 66 achieved clinical success in the primary treated joint (86%; 95% confidence interval: 76% to 93%), confirming the efficacy of collagenase clostridium histolyticum injections. mor ... | 2016 | 27313184 |
| adipose tissue microbiota in humans: an open issue. | a specific 'adipose tissue' microbiota has been recently identified in mice and hypothesized in humans. the purpose of this study was to verify the presence of microbiota of human whole adipose tissue and isolated adipocytes by combining culture-dependent and independent methods. | 2016 | 27297798 |
| a non-aggressive, highly efficient, enzymatic method for dissociation of human brain-tumors and brain-tissues to viable single-cells. | conducting research on the molecular biology, immunology, and physiology of brain tumors (bts) and primary brain tissues requires the use of viably dissociated single cells. inadequate methods for tissue dissociation generate considerable loss in the quantity of single cells produced and in the produced cells' viability. improper dissociation may also demote the quality of data attained in functional and molecular assays due to the presence of large quantities cellular debris containing immune-a ... | 2016 | 27251756 |
| association between infertility and sexual dysfunction in men and women. | the relation between infertility and sexual dysfunction can be reciprocal. causes of sexual dysfunction that affect fertility include erectile dysfunction, peyronie's disease (abnormal penile curvature), low libido, ejaculatory disorders in men, and genito-pelvic pain/penetration disorder (gpppd) and low sexual desire in women. | 2016 | 27872029 |
| impact of number of cycles of collagenase clostridium histolyticum on outcomes in patients with peyronie's disease. | to analyze the impact of the number of cycles of collagenase clostridium histolyticum (cch) intralesional injection therapy on outcomes to further characterize cch therapy. | 2017 | 27816605 |
| loss of stiffness in collagen-rich uterine fibroids after digestion with purified collagenase clostridium histolyticum. | uterine fibroids are a significant health problem. these common benign tumors occur in 70-80% of women before age 50 years and often cause bleeding and pain and can interfere considerably with daily life. current treatment options are limited. fibroids contain substantial amounts of altered and disordered collagens, which contribute to their bulk. targeting these collagens directly presents a novel treatment approach. | 2016 | 27177523 |
| the history of collagenase clostridium histolyticum. | after its u.s. fda approval in 2013, collagenase clostridium histolyticum (cch) has seen increasing use as a nonoperative treatment for peyronie's disease (pd). we review the history of cch and trials that led to its adoption. | 2015 | 27784601 |
| survey of patient and partner satisfaction following collagenase clostridium histolyticum treatment for peyronie's disease. | intralesional injection of collagenase clostridium histolyticum (cch) is a minimally invasive, food and drug administration-approved, effective treatment for peyronie's disease (pd). to assess the satisfaction of patients and their female sexual partners (fsp) following cch therapy for pd, we conducted a retrospective review of the records of all patients treated with cch for pd between 04/2014 and 03/2016. collected variables included demographics, pre- and post-treatment sexual function, penil ... | 2017 | 28187522 |
| adverse effects of collagenase in the treatment of dupuytren disease: a systematic review. | collagenase clostridium histolyticum (cch) has proven to be both safe and effective in the treatment of dupuytren disease (dd). the medium-term outcomes are similar to those achieved with surgery, and most adverse effects are self-limiting and considered to be mild or moderate. | 2017 | 28181175 |
| pain associated with treatment of dupuytren contracture with collagenase clostridium histolyticum. | the primary objective of this study was to quantify the degree of pain associated with collagenase clostridium histolyticum (cch) injection and to determine whether it is related to other factors in the intervention. | 2017 | 28160905 |
| [treatment of dupuytren's disease with collagenase clostridium histolyticum]. | dupuytren's disease as a benign fibroproliferative disease leads to hyperplasia of the collagen fibers of the fascia of the palm, which can result in severe impairment of the functionality of the hand. | 2017 | 28138723 |
| effect of freeze-dried allograft bone with human basic fibroblast growth factor containing a collagen-binding domain from clostridium histolyticum collagenase on bone formation after lumbar posterolateral fusion surgery in rats. | an experimental study. | 2017 | 28098745 |
| in vitro extraction and fermentation of polyphenols from grape seeds (vitis vinifera) by human intestinal microbiota. | the effects of several parameters on the extraction yield of total polyphenols from grape seeds by pressurized liquid extraction were investigated. the highest recovery of total polyphenols occurred at 80 °c within 5 min, and a single extraction allowed a recovery of more than 97% of total polyphenols. following the purification with macroporous resin, the effects of grape polyphenols (>94.8%) on human intestinal microbiota were monitored over 36 h incubation by fluorescence in situ hybridizatio ... | 2016 | 26980065 |
| the modulatory effect of anthocyanins from purple sweet potato on human intestinal microbiota in vitro. | in order to investigate the modulatory effect of purple sweet potato anthocyanins (pspas) on human intestinal microbiota, pspas were prepared by column chromatography and their influence on intestinal microbiota was analyzed by monitoring the bacterial populations and analyzing short-chain fatty acid (scfa) concentrations at different time points. the numbers (log10 cell/ml) of bifidobacterium and lactobacillus/enterococcus spp., bacteroides-prevotella, clostridium histolyticum, and total bacter ... | 2016 | 26975278 |
| peyronie's disease: what's around the bend? | peyronie's disease (pd) is a fibrotic diathesis of the tunica albuginea that results in penile plaque formation and penile deformity, negatively affecting sexual and psychosocial function of both patients and their partners. in this review, we discuss the pd literature and pd treatment options, with special emphasis on potential future therapies. | 2017 | 26941488 |
| trends in the treatment of dupuytren disease in the united states between 2007 and 2014. | background: dupuytren disease is a common fibroproliferative disorder. multiple procedural treatment options are available, with collagenase clostridium histolyticum (cch) injection being introduced in 2010. the purpose of this study was to investigate trends in the treatment of dupuytren disease in the united states between 2007 and 2014. methods: the pearldiver humana database was queried using international classification of diseases, ninth revision (icd-9) and current procedural terminology ... | 2017 | 28082837 |
| intralesional collagenase clostridium histolyticum study provides real-world analysis. | | 2016 | 28078227 |
| collagenase clostridium histolyticum for the treatment of peyronie's disease: a 'real world' clinical perspective. | the introduction of collagenase clostridium histolyticum (cch) as a treatment option for peyronie's disease (pd), defined as the abnormal formation of collagen on the tunica albuginea of the penis, has provided patients with a promising new conservative therapy. studies have shown that cch improves curvature by an average of 17°, and although patient and sexual partner satisfaction is high, the improvement has arguable clinical implications. similarly, the efficacy and cost of cch contrasts stro ... | 2016 | 27770352 |
| to remember: radiotherapy - a successful treatment for early dupuytren's disease. | dupuytren's disease (dd) is a common fibroproliferative condition of the hand which tends to cause progressive digital flexion contracture. therapeutic strategies to treat the disease include radiotherapy, injections of collagenase clostridium histolyticum, needle fasciotomy and extended surgical intervention dependent on involvement and duration of the disease. we have reviewed the literature with the aim to assess the conditions and effects of radiotherapy in dd. in early stages of the disease ... | 2016 | 27428598 |
| long-term effects of the collagenase of the bacterium clostridium histolyticum for the treatment of capsular fibrosis after silicone implants. | capsular contracture remains the most frequent long-term complication after augmentation mammoplasty with silicone implants. thereby, the main part of the fibrotic capsule is collagen. the collagenase of the bacterium clostridium histolyticum is approved for the treatment of fibrotic diseases and has been demonstrated to be effective for capsular fibrosis treatment in the short term. however, long-term effectiveness is currently unknown but mandatory for clinical utilization. | 2017 | 28008464 |
| effectiveness and safety of collagenase clostridium histolyticum in dupuytren's disease : an observational study in belgium. | dupuytren's disease is a connective tissue disorder leading to contractures. it can be treated surgically or through injections of collagenase clostridium histolyticum (cch). patients with dupuytren's contracture (> 20°) and a palpable cord were included in this observational study, aiming to characterise the belgian patient population and to assess the effectiveness and safety of cch. overall, 108 patients (114 joints) received at least one injection of cch, and 104 patients completed the study ... | 2016 | 27682305 |
| purification and fermentation in vitro of sesaminol triglucoside from sesame cake by human intestinal microbiota. | sesaminol triglucoside (stg), the most abundant lignan glycoside existing in sesame cake/meal, has exhibited various biological activities. however, little information about its in vitro fermentation with intestinal microbiota is available. therefore, the effect of stg from sesame cake on the fermentation of human fecal microbiota was evaluated. first, high-purity stg was successfully prepared from defatted sesame cake by extraction with 80% ethanol and simple purification procedures of polyamid ... | 2013 | 23387872 |
| effects of cocoa husk feeding on the composition of swine intestinal microbiota. | a two-diet/two-period change over experiment was performed to investigate the effects of cocoa husks, as a source of dietary fiber and polyphenols, on pig intestinal microbial composition. six pigs were fed a conventional cereal-based diet or a diet obtained by substitution of 7.5% of the conventional diet with cocoa husks for 3 weeks. experimental diets were isoproteic and isoenergetic. at the end of each 3 week testing period, samples of fresh feces were collected and analyzed for microbial co ... | 2016 | 26877143 |
| the use of residual collagenase for single digits with multiple-joint dupuytren contractures. | standard 0.58 mg (0.25 ml) collagenase clostridium histolyticum (cch) preparations result in unused cch that is often discarded. our purpose was to assess the results on dupuytren contractures affecting both the metacarpophalangeal (mcp) and proximal interphalangeal (pip) joints in the same digit utilizing an injection containing the maximum cch volume that can be withdrawn from a single vial. | 2017 | 28389081 |
| clinical experience with penile traction therapy among men undergoing collagenase clostridium histolyticum for peyronie's disease. | to evaluate the outcomes in men undergoing collagenase clostridium histolyticum (cch) with concurrent penile traction therapy (ptt) for the treatment of peyronie's disease (pd). | 2017 | 28347795 |
| toxic dermatitis secondary to treatment with collagenase clostridium histolyticum for dupuytren´s disease. | secondary effects and drug reactions relative to collagenase clostridium histolyticum treatment for dupuytren's contracture are frequent. in only a few cases these secondary effects are considered serious. the mechanism that produces these effects of production is not well understood. | 2016 | 27649672 |
| [comparative cost effectiveness of clostridium histolyticum collagenase (xiapex®) and partial fasciectomy for the treatment of dupuytren's contracture in austria]. | since dupuytren's contracture is a common disorder, the costs for its surgical treatment impose a considerable burden on the healthcare system. for the first time in the german-speaking area, this study aimed to provide a comparative cost-effectiveness analysis for partial fasciectomy vs. treatment with clostridium histolyticum collagenase (cch). | 2016 | 27547932 |
| the impact of collagenase clostridium histolyticum introduction on dupuytren treatment patterns in the united states. | the u.s. food and drug administration approved the use of collagenase clostridium histolyticum (cch) in the united states in february 2010. this study addresses the impact of that approval on the number of dupuytren contracture (dc) encounters and treatment patterns in the united states. | 2016 | 27546441 |
| review of management options for patients with atypical peyronie's disease. | peyronie's disease (pd) is a wound-healing disorder of the tunica albuginea often associated with penile deformity. less commonly, patients with pd might display atypical presentations such as ventral curvature, hourglass deformity, significantly shortened penis, and/or multiplanar curvature. | 2017 | 27544298 |
| in vitro studies to evaluate the wound healing properties of calendula officinalis extracts. | calendula officinalis (pot marigold) flower extracts have a long-lasting tradition in ethnopharmacology. currently, the european medicines agency (ema) has approved its lipophilic and aqueous alcoholic extracts as traditional medicinal products for the treatment of minor inflammation of the skin and as an aid in the healing of minor wounds. | 2017 | 27956358 |
| efficacy and safety of the collagenase of the bacterium clostridium histolyticum for the treatment of capsular contracture after silicone implants: ex-vivo study on human tissue. | the fibrotic capsule that surrounds silicone implants consists mainly of collagen. the fda-approved collagenase of the bacterium clostridium histolyticum provides a reasonable treatment option. safety and efficacy at the female breast site must be evaluated before clinical utilization. | 2016 | 27232716 |
| peyronie's disease and injectable collagenase clostridium histolyticum: safety, efficacy, and improvements in subjective symptoms. | to report on an early adopter series of collagenase clostridium histolyticum (cch) for peyronie's disease (pd). postapproval studies of cch have been anticipated after recent food and drug administration authorization of its use for men with pd as definitive and durable nonsurgical interventions have been long desired. | 2016 | 27211926 |
| corr(®) ors richard a. brand award: clinical trials of a new treatment method for adhesive capsulitis. | conservative and even surgical management of adhesive capsulitis often is prolonged and painful. management of adhesive capsulitis is lacking evidence-based controlled clinical trials. | 2016 | 27160746 |
| collagenase clostridium histolyticum in dupuytren's contracture: a systematic review. | in the last few years, the use of collagenase clostridium histolyticum for management of dupuytren's contracture has increased. the procedure of enzymatic fasciectomy has become popular because it is non-invasive, safe and fast to perform. | 2016 | 27151958 |
| patient satisfaction with collagenase. | to establish patient satisfaction after collagenase clostridium histolyticum (cch) injection. | 2016 | 27132016 |
| [effects of exogenous enzymes on the degradation of adhesive-dentin interfaces]. | to compare the effects of exogenous enzymes on the degradation of adhesive-dentin interface. | 2016 | 27117216 |
| collagenase clostridium histolyticum: emerging practice patterns and treatment advances. | this study aims to provide a comprehensive review of the role of collagenase clostridium histolyticum (cch). | 2016 | 27050718 |
| results of smsna survey regarding complications following intralesional injection therapy with collagenase clostridium histolyticum for peyronie's disease. | intralesional injection of collagenase clostridium histolyticum (cch) for peyronie's disease (pd) can result in serious adverse events such as hematoma formation and corporal rupture. | 2016 | 27045265 |
| acceleration of bone formation during fracture healing by poly(pro-hyp-gly)10 and basic fibroblast growth factor containing polycystic kidney disease and collagen-binding domains from clostridium histolyticum collagenase. | growth factor delivered in combination with animal-derived collagen materials has been used to accelerate bone fracture healing in human patients. however, the introduction of bovine proteins into humans carries the risk of zoonotic and immunologic complications. here, we developed a collagen-like polypeptide-based bone formation system consisting of poly(pro-hyp-gly)10 , which mimics the triple helical conformation of collagen, and basic fibroblast growth factor (bfgf) fused to the polycystic k ... | 2016 | 26833780 |
| dtb select: 2 | february 2016. | evidence for fibrates in secondary prevention of cvd ● impact of comorbidity on benefits of commonly prescribed drugs ● identifying patients at risk of inappropriate prescribing ● shared decision making to reduce antibiotic prescribing in primary care ● duration of bcg vaccine protection ● antivirals for bell's palsy revisited ● time to review blood pressure targets? ● adherence to computerised cbt in primary care ● collagenase clostridium histolyticum for dupuytren's contracture. | 2016 | 26825794 |
| collagenase treatment for dupuytren disease of the thumb and first web. | to evaluate the short-term effectiveness of collagenase clostridium histolyticum to treat thumb and first web contractures in dupuytren disease. | 2016 | 26803569 |
| does collagenase injection disrupt or digest the dupuytren's cord: a magnetic resonance imaging study. | collagenase clostridium histolyticum has been extensively studied as a treatment modality for dupuytren's contracture. its mechanism of action has been documented. it is unknown whether injected collagenase weakens the dupuytren's cord sufficiently to cause failure during manipulation or if there is digestion and reduction in cord volume. we examined five patients with isolated contractures of the ring or middle metacarpalphalangeal (mp) joint using magnetic resonance imaging (mri) prior to inje ... | 2016 | 26768221 |
| reply: salvage palmar fasciectomy following initial treatment with collagenase clostridium histolyticum. | | 2016 | 26741890 |
| salvage palmar fasciectomy after initial treatment with collagenase clostridium histolyticum. | | 2016 | 26741888 |
| collagenase clostridium histolyticum in the management of peyronie's disease: a review of the evidence. | peyronie's disease (pd) is a connective tissue disorder resulting in the abnormal accumulation of scar or plaques in the tunica albuginea of the penis. the condition is characterized by two phases: an active, inflammatory phase, and a stable, chronic phase. collagenase clostridium histolyticum (cch) was isolated in the mid-1900s and postulated as a potential pharmacologic strategy for breaking down the abnormal connective tissue plaques of pd. prior to the introduction of cch, a wide variety of ... | 2016 | 27247629 |
| outcome of dupuytren's contractures after collagenase clostridium histolyticum injection: a single institution experience. | | 2015 | 26397518 |
| [effect of dopamine on the activity of matrix metalloproteinases and degradation of dentin collagen]. | to investigate the inhibition effect of dopamine on the activity of matrix metalloproteinases (mmp) and the effect of dopamine on degradation of dentin collagen for its potential use in caries treatment and dentin adhesive. | 2015 | 26081862 |
| collagenase clostridium histolyticum for the pharmacological management of peyronie's disease. | peyronie's disease (pd) is defined as the abnormal accumulation of connective tissue in the tunica albuginea of the penis, and is an ongoing physical and psychological challenge for thousands of americans. in vitro studies in the 1950s uncovered the potential of collagenase clostridium histolyticum (cch) to disrupt the collagen-containing plaques in pd, and opened the door to more in-depth clinical trials. results indicated that with multiple dosage cycles followed by plaque modeling, penile cur ... | 2015 | 26380384 |
| delayed manipulation after collagenase clostridium histolyticum injection for dupuytren contracture. | collagenase clostridium histolyticum (cch) injection for dupuytren contracture was approved in the usa in 2010. current fda guidelines stipulate that finger manipulation occurs the day following injection. to investigate the safety and efficacy of delaying manipulation to 2 or 4 days following cch injection, we conducted a prospective, randomized trial at two sites. | 2015 | 26330801 |
| new insights into the immediate outcome of collagenase injections for dupuytren's contracture. | collagenase clostridium histolyticum is now established as an effective and safe option to treat patients with a single joint affected with dupuytren's contracture. we have extended its use to natatory and combined cords. in a prospective consecutive series of 298 cords in 237 patients, the mean total extension loss improved in cords crossing the metacarpophalangeal joint from 46° to 1°, in cords crossing the proximal interphalangeal joint from 56° to 7°, in natatory cords from 130° to 25° and i ... | 2016 | 26307140 |
| re: surgical correction of persistent peyronie's disease following collagenase clostridium histolyticum treatment. | | 2015 | 26292883 |
| a single injection of collagenase clostridium histolyticum for the treatment of moderate dupuytren's contracture: a 2 year follow-up of 47 patients. | | 2016 | 26269508 |
| secretor status is strongly associated with microbial alterations observed during pregnancy. | during pregnancy there are significant changes in gut microbiota composition and activity. the impact of secretor status as determined by genotyping fut2 (fucosyltransferase 2) gene was taken as one of the confounding factors associated with faecal microbiota changes during pregnancy. in this prospective study, we followed women during pregnancy (total = 123 of which secretors = 108, non-secretors = 15) and characterised their gut microbiota by quantitative polymerase chain reaction (qpcr), fluo ... | 2015 | 26231005 |
| the efficacy and safety of concurrent collagenase clostridium histolyticum injections for 2 dupuytren contractures in the same hand: a prospective, multicenter study. | to evaluate efficacy and safety of concurrent administration of 2 collagenase clostridium histolyticum (cch) injections to treat 2 joints in the same hand with dupuytren fixed flexion contractures (ffcs). | 2015 | 26216077 |
| collagenase clostridium histolyticum: a review in peyronie's disease. | collagenase clostridium histolyticum (cch) (xiaflex(®), xiapex(®)) intralesional injection is a mixture of class i (aux-i) and class ii (aux-ii) clostridial collagenases. it is indicated for the treatment of adult men with peyronie's disease with a palpable plaque and curvature deformity of ≥ 30° at the start of therapy. this article reviews the efficacy and tolerability of cch in this indication and briefly summarizes its pharmacology. cch treatment significantly improved penile curvature defor ... | 2015 | 26201462 |
| self-report and clinical response to peyronie's disease treatment: peyronie's disease questionnaire results from 2 large double-blind, randomized, placebo-controlled phase 3 studies. | to evaluate the clinical usefulness of the peyronie's disease questionnaire (pdq). the relationship between subject-reported changes in pdq psychosexual symptoms and clinical response to peyronie's disease (pd) treatment was examined. | 2015 | 26199168 |
| the collagenase of the bacterium clostridium histolyticum for the treatment of capsular fibrosis after silicone implants. | the main part of the fibrotic capsule in capsular contracture is collagen. the collagenase of the bacterium clostridium histolyticum is u.s. food and drug administration approved for the treatment of dupuytren contracture and might be capable of dissolving the fibrotic capsule surrounding silicone implants. | 2015 | 26171751 |
| intralesional injection of interferon-α2b improves penile curvature in men with peyronie's disease independent of plaque location. | collagenase clostridium histolyticum is the only fda (food and drug administration) approved treatment for peyronie's disease. however, to our knowledge collagenase clostridium histolyticum has not been studied in men with ventral plaques. given this limitation and the paucity of literature on ventral plaque outcomes, we compared the results of peyronie's disease treatment in men with different plaque locations treated with intralesional interferon-α2b. | 2015 | 26144333 |
| collagenase clostridium histolyticum (xiaflex) for the treatment of urethral stricture disease in a rat model of urethral fibrosis. | to evaluate the treatment effect of collagenase clostridium histolyticum (cch) in a rat model of urethral fibrosis. | 2015 | 26126692 |
| therapeutic advances in the treatment of peyronie's disease. | peyronie's disease (pd) is an under-diagnosed condition with prevalence in the male population as high as 9%. it is a localized connective tissue disorder of the penis characterized by scarring of the tunica albuginea. its pathophysiology, however, remains incompletely elucidated. for the management of the acute phase of pd, there are currently numerous available oral drugs, but the scientific evidence for their use is weak. in terms of intralesional injections, collagenase clostridium histolyti ... | 2015 | 26097120 |
| effects of different concentrations of injectable collagenase enzyme on capsular tissue around silicone implants: a preliminary experimental study for the development of a new treatment strategy. | in recent studies, collagen organization was blamed for the formation of capsular contracture which is still a challenging problem after silicone implant-based breast operations. in this study, effects of different concentrations of collagenase enzyme derived from clostridium histolyticum on the capsular tissue formation around the silicone implants were investigated. the injectable form of collagenase has a routine clinical use in the treatment of both dupuytren's and peyronie's diseases. | 2016 | 26715576 |
| injectable collagenase clostridium histolyticum as a nonsurgical treatment for dupuytren's disease. | nonsurgical treatment of dupuytren's disease using collagenase clostridium histolyticum (cch). | 2016 | 26683416 |
| effect of enzymatic debridement with two different collagenases versus mechanical debridement on chronic hard-to-heal wounds. | a chronic ulcer is usually defined as an injury that does not spontaneously evolve towards healing and does not progress through normal healing stages such as inflammation, proliferation and remodelling. this study was designed in order to compare two types of collagenases with mechanical debridement alone. it was thus possible to evaluate their differences in terms of pain and debridement efficacy. patients were divided into three groups: 30 patients were daily dressed using an ointment based o ... | 2016 | 25649929 |
| [treatment of dupuytren's disease with collagenase - a 1-year follow-up of 37 patients]. | the efficiency of collagenase of clostridium histolyticum (cch; xiapex) in the treatment of dupuytren's contracture has been proved in phase iii studies. this retrospective study aims to evaluate our clinical results after the use of cch. | 2014 | 25564949 |
| postapproval clinical experience in the treatment of dupuytren's contracture with collagenase clostridium histolyticum (cch): the first 1,000 days. | dupuytren's contracture is a benign fibromatosis of the palmar and digital fascia of the hand of uncertain etiology, resulting in nodules and cords beneath the skin of the palm of the hands that may lead to the development of contractures. surgical intervention is often considered when metacarpophalangeal (mp) joint contracture is 30° or more, or when there is any degree of proximal interphalangeal (pip) joint contracture. collagenase clostridium histolyticum (cch) is a nonsurgical, minimally in ... | 2014 | 25414604 |
| clostridium histolyticum collagenase - is this a revolutionary medical treatment for peyronie's disease? | | 2016 | 26683137 |
| temporal evolution of mri characteristics in dogs with collagenase-induced intracerebral hemorrhage. | intracerebral hemorrhage (ich) is one of the most lethal types of stroke. neuroimaging techniques, particularly mri, have improved the diagnostic accuracy of ich. the mri characteristics of the evolving stages of ich in humans-but not those in dogs-have been described. in this study, we document the temporal mri characteristics in a canine model of collagenase-induced ich. specifically, ich was induced in 5 healthy beagles by injecting 500 u of bacterial collagenase from clostridium histolyticum ... | 2015 | 26678369 |
| collagenase clostridium histolyticum for the treatment of dupuytren's contracture: systematic review and economic evaluation. | dupuytren's disease is a slowly progressive condition of the hand, characterised by the formation of nodules in the palm that gradually develop into fibrotic cords. contracture of the cords produces deformities of the fingers. surgery is recommended for moderate and severe contractures, but complications and/or recurrences are frequent. collagenase clostridium histolyticum (cch) has been developed as a minimally invasive alternative to surgery for some patients. | 2015 | 26524616 |
| letter regarding "dupuytren contracture recurrence following treatment with collagenase clostridium histolyticum (cordless [collagenase option for reduction of dupuytren long-term evaluation of safety study]): 5-year data". | | 2015 | 26518325 |
| evaluation of species differences and the effects of storage duration and temperature on the anticollagenase efficacy of canine, feline, and equine serum on in vitro corneal degradation. | objective to evaluate species differences and effects of storage duration and temperature on the anticollagenase efficacy of canine, feline, and equine serum on in vitro corneal degradation. samples corneas and serum from dogs, cats, and horses. procedures clinically normal corneas from dogs, cats, and horses were harvested within 2 hours after euthanasia. serum samples from dogs, cats, and horses were collected and pooled by species. corneal specimens were incubated with collagenase derived fro ... | 2015 | 26512545 |
| role of collagenase clostridium histolyticum in peyronie's disease. | peyronie's disease is a localized connective tissue disease characterized by an active, inflammatory phase and a stable, quiescent phase, with the eventual development of collagenous plaques within the tunica albuginea of the penis. risk factors primarily associated with peyronie's disease include dupuytren's contracture, penile trauma, and family history. a variety of treatment strategies have been utilized, including oral and topical agents, electromotive drug administration, intralesional inj ... | 2015 | 26491251 |
| restoration of penile function and patient satisfaction with intralesional collagenase clostridium histolyticum injection for peyronie's disease. | collagenase clostridium histolyticum is approved for the treatment of peyronie's disease. to date, no post-release study to our knowledge has evaluated patient perceived outcomes and satisfaction. therefore, we evaluated patient perceived experience with collagenase clostridium histolyticum injection for peyronie's disease in a clinical practice. | 2016 | 26476353 |
| dupuytren contracture recurrence following treatment with collagenase clostridium histolyticum (cordless [collagenase option for reduction of dupuytren long-term evaluation of safety study]): 5-year data. | collagenase option for reduction of dupuytren long-term evaluation of safety study was a 5-year noninterventional follow-up study to determine long-term efficacy and safety of collagenase clostridium histolyticum (cch) treatment for dupuytren contracture. | 2015 | 26096221 |
| re: clinical efficacy of collagenase clostridium histolyticum in the treatment of peyronie's disease by subgroups: results from two large, double-blind, randomized, placebo-controlled, phase iii studies. | | 2015 | 26460876 |
| effect of enzymatic hydrolysis on surface activity and surface rheology of type i collagen. | we describe the adsorption behaviour and rheological properties of a calf skin type i collagen, and of its hydrolysates obtained using a clostridium histolyticum collagenase (chc) under moderate conditions (ph 7, 37°c). the effect of chc concentration (2×10(-9)-2×10(-6)m) and incubation time (35-85min) was studied and optimised to achieve the highest decrease of surface tension and the highest dilational surface viscoelasticity of the adsorbed layers. sds-page electrophoresis and reverse-phase h ... | 2016 | 26032978 |
| salvage palmar fasciectomy after initial treatment with collagenase clostridium histolyticum. | collagenase clostridium histolyticum was approved for clinical use in 2010 and has become an accepted treatment modality for dupuytren's contracture. because longitudinal experience with injectable collagenase remains limited, the effect of treatment on future surgery is not well defined. | 2015 | 26017606 |
| engineering d-amino acid containing collagen like peptide at the cleavage site of clostridium histolyticum collagenase for its inhibition. | collagenase is an important enzyme which plays an important role in degradation of collagen in wound healing, cancer metastasis and even in embryonic development. however, the mechanism of this degradation has not yet been completely understood. in the field of biomedical and protein engineering, the design and development of new peptide based materials is of main concern. in the present work an attempt has been made to study the effect of dala in collagen like peptide (imino-poor region of type ... | 2015 | 25973613 |
| acceleration of callus formation during fracture healing using basic fibroblast growth factor-kidney disease domain-collagen-binding domain fusion protein combined with allogenic demineralized bone powder. | to repair fractures with large bone defects or gaps, demineralized allogenic bone matrix (dbm) is often applied to the fracture site. however, studies have shown that the use of dbm alone has limited efficacy for repairing fractures. in the present study, we developed an allogenic demineralized bone powder (dbp) with basic fibroblast-derived growth factor containing a polycystic kidney disease (pkd) domain and collagen-binding domain (cbd) from clostridium histolyticum collagenase (colh) and inv ... | 2015 | 25956801 |
| collagenase clostridium histolyticum for the treatment of peyronie's disease: the development of this novel pharmacologic approach. | the conception of collagenase clostridium histolyticum (cch) as treatment for peyronie's disease (pd) was a vital first step in providing a nonsurgical, minimally invasive fda-approved treatment for men with pd. | 2015 | 25940867 |
| pharmacologic therapy for peyronie's disease: what should we prescribe? | peyronie's disease (pd) is a wound healing disorder of the penis with a myriad of proposed treatment options reported in the literature. evaluating the available data and therapeutic management of pd can be challenging and confusing, even for the most experienced treating physician. this review provides a comprehensive overview of pharmacologic treatment options for pd, focusing on the best available evidence. | 2015 | 25927285 |
| efficacy and safety of collagenase clostridium histolyticum in the treatment of proximal interphalangeal joints in dupuytren contracture: combined analysis of 4 phase 3 clinical trials. | to examine the results of proximal interphalangeal (pip) joint contractures from 4 phase 3 clinical trials of collagenase clostridium histolyticum (cch) injection for dupuytren contracture. | 2015 | 25843533 |
| collagenase clostridium histolyticum versus limited fasciectomy for dupuytren's contracture: outcomes from a multicenter propensity score matched study. | controversy exists about the relative effectiveness of injectable collagenase (collagenase clostridium histolyticum) and limited fasciectomy in the treatment of dupuytren's contracture. the authors compared the effectiveness of both techniques in actual clinical practice. | 2015 | 25829153 |
| analysis of the clinical safety of intralesional injection of collagenase clostridium histolyticum (cch) for adults with peyronie's disease (pd). | to examine the safety of intralesional injection of collagenase clostridium histolyticum (cch) for the treatment of peyronie's disease (pd), using a pooled safety analysis of patients who received at least one dose of cch in any of six clinical studies. | 2015 | 25818264 |
| synergistic effect of neutral protease and clostripain on rat pancreatic islet isolation. | islet isolation currently requires collagenase, neutral protease and other components. thermolysin (tl) from bacillus thermoproteolyticus is the gold standard neutral protease. however, we speculated that neutral protease derived from clostridium histolyticum (ch; chnp) would be biologically superior for islet isolation. tryptic-like activity has also been reported to be important. therefore, we focused on clostripain (cp), since it is one of the main proteases in clostridium histolyticum which ... | 2015 | 25803499 |
| enhancement of periosteal bone formation by basic fibroblast-derived growth factor containing polycystic kidney disease and collagen-binding domains from clostridium histolyticum collagenase. | recombinant basic fibroblast growth factor (bfgf) is a potent mitogen for mesenchymal cells that accelerates bone union and repair when applied locally at defect sites. however, because bfgf diffuses rapidly from bone defect sites, repeated dosing is required for sustained therapeutic effect. we previously fused the collagen-binding domain (cbd) and polycystic kidney disease (pkd) domain of clostridium histolyticum class ii collagenase (colh) to bfgf and demonstrated that the fusion protein mark ... | 2017 | 25783848 |
| clinical safety and effectiveness of collagenase clostridium histolyticum injection in patients with peyronie's disease: a phase 3 open-label study. | collagenase clostridium histolyticum (cch; xiaflex, auxilium pharmaceuticals, inc., chesterbrook, pa, usa) is a food and drug administration-approved, intralesional treatment for peyronie's disease (pd). | 2015 | 25388099 |
| surgical correction of persistent peyronie's disease following collagenase clostridium histolyticum treatment. | collagenase clostridium histolyticum (cch) is an food and drug administration-approved intralesional injection for treatment of peyronie's disease (pd) that has been shown to reduce penile curvature deformity and pd symptom bother in phase 2b and phase 3 placebo-controlled clinical trials. for some patients, nonsurgical treatment with cch may not sufficiently improve penile curvature, and surgical correction may be pursued following cch therapy. | 2015 | 25345351 |
| injectable clostridium histolyticum collagenase as a potential treatment for uterine fibroids. | purified clostridium histolyticum collagenase (chc), an food and drug administration-approved drug that does not affect nerves or blood vessels, was assessed as a potential treatment for fibroids in this proof-of-principle study. fibroids (1-4 cm, capsules intact) and myometrial specimens from 5 patients were injected posthysterectomy with chc or vehicle containing methylene blue and incubated for 24 hours. percentage of collagen-stained area was estimated using masson-trichrome-stained slides. ... | 2014 | 25332216 |
| 2013-2014 updates in peyronie's disease management. | the number of patients presenting with peyronie's disease (pd) appears to be on the rise. this review provides an analysis of pertinent recent updates in the management of pd, focusing on data published within the past year. objective benefit from injectable agents has been reported for years in mostly noncontrolled trials. the safety and efficacy of injectable collagenase clostridium histolyticum is now supported by data from a large-scale phase iii randomized controlled trial. other important ... | 2014 | 25287257 |
| first identification of resident and circulating fibrocytes in dupuytren's disease shown to be inhibited by serum amyloid p and xiapex. | dupuytren's disease (dd) is a common progressive fibroproliferative disorder causing permanent digital contracture. proliferative myofibroblasts are thought to be the cells responsible for dd initiation and recurrence, although their source remains unknown. dd tissue has also been shown to harbor mesenchymal and hematopoietic stem cells. fibrocytes are circulating cells that show characteristics of fibroblasts and they express surface markers for both hematopoietic and mesenchymal stromal cells. ... | 2014 | 24933153 |
| resource utilisation associated with single digit dupuytren's contracture treated with either surgery or injection of collagenase clostridium histolyticum. | the gold standard treatment for dupuytren's contracture is surgical excision of the cord. a non-surgical treatment with collagenase clostridium histolyticum injection is available but appears costly. | 2014 | 24875504 |
| acceleration of bone union after structural bone grafts with a collagen-binding basic fibroblast growth factor anchored-collagen sheet for critical-size bone defects. | bone allografts are commonly used for the repair of critical-size bone defects. however, the loss of cellular activity in processed grafts markedly reduces their healing potential compared with autografts. to overcome this obstacle, we developed a healing system for critical-size bone defects that consists of overlaying an implanted bone graft with a collagen sheet (cs) loaded with basic fibroblast growth factor (bfgf) fused to the collagen-binding domain derived from a clostridium histolyticum ... | 2014 | 24844188 |
| experience in the use of collagenase clostridium histolyticum in the management of peyronie's disease: current data and future prospects. | peyronie's disease (pd) is a chronic wound-healing disorder characterized by formation of fibrous inelastic scarring of the tunica albuginea resulting in a variety of penile deformities. in most cases, pd is accompanied by a physical and psychological impact. xiaflex® is an injectable collagenase clostridium histolyticum (cch) preparation consisting of a predetermined mixture of two distinct collagenases. recently the us food and drug administration (fda) approved xiaflex® for the nonsurgical tr ... | 2014 | 25276229 |
| prospective randomized controlled trial comparing 1- versus 7-day manipulation following collagenase injection for dupuytren contracture. | to compare the efficacy, tolerance, and safety of manual manipulation at day 7 to day 1 following collagenase clostridium histolyticum (cch) injection for dupuytren contracture. | 2014 | 25194768 |
| collagenase clostridium histolyticum injection for plantar fibromatosis (ledderhose disease). | | 2014 | 25158740 |
| what is the better treatment for single digit dupuytren's contracture: surgical release or collagenase clostridium histolyticum (xiapex) injection? | the purpose of this study was to compare the initial and final outcome range of motion in the mcp-j and pip-j of single digit dupuytren's contracture treated with either open surgical excision or manipulation after collagenase clostridium histolyticum (cch; xiapex) injection. | 2014 | 25155703 |
| cold intolerance following collagenase clostridium histolyticum treatment for dupuytren contracture: a molecular mechanism. | | 2014 | 25154579 |
| peyronie's disease: review and recent advances. | peyronie's disease is an incurable, sexually debilitating fibrotic disease of the penis that results in penile curvature, coital failure, and significant psychological stress for patients and their partners. appropriate treatment should be individualized and tailored to the patient's goals and expectations, disease history, physical exam findings, and erectile function. while medical treatments exist, there is little evidence to support their use. high-quality data supporting more recent advance ... | 2014 | 24984940 |